Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OCX 
OncoCyte Corp (OCX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: OCX (1-star) is a SELL. SELL since 5 days. Profits (-18.67%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.42
1 Year Target Price $5.42
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.76% | Avg. Invested days 27 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 91.52M USD | Price to earnings Ratio - | 1Y Target Price 5.42 |
Price to earnings Ratio - | 1Y Target Price 5.42 | ||
Volume (30-day avg) 4 | Beta 0.99 | 52 Weeks Range 1.92 - 4.75 | Updated Date 06/30/2025 |
52 Weeks Range 1.92 - 4.75 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.79 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -273.01% |
Management Effectiveness
Return on Assets (TTM) -22.17% | Return on Equity (TTM) -428.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 63680719 | Price to Sales(TTM) 23.81 |
Enterprise Value 63680719 | Price to Sales(TTM) 23.81 | ||
Enterprise Value to Revenue 16.57 | Enterprise Value to EBITDA -1.25 | Shares Outstanding 28599300 | Shares Floating 7754982 |
Shares Outstanding 28599300 | Shares Floating 7754982 | ||
Percent Insiders 22.03 | Percent Institutions 56.3 |
Analyst Ratings
Rating 2 | Target Price 5.42 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
OncoCyte Corp
Company Overview
History and Background
OncoCyte Corporation was founded in 2009. It focuses on developing and commercializing non-invasive liquid biopsy tests for early cancer detection.
Core Business Areas
- DetermaRx: A gene expression test designed to predict chemotherapy response in early-stage lung cancer patients.
Leadership and Structure
The leadership team includes key executives in roles such as CEO, CFO, and Chief Medical Officer. The organizational structure involves departments for research and development, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- DetermaRx: Predicts chemotherapy response in early-stage lung cancer. Market share data is not widely available. Competitors include companies offering similar predictive tests, and standard pathological assessment.
Market Dynamics
Industry Overview
The liquid biopsy market is growing rapidly, driven by the increasing need for non-invasive cancer diagnostics.
Positioning
OncoCyte aims to establish itself as a leader in the lung cancer diagnostic space with its DetermaRx test.
Total Addressable Market (TAM)
The total addressable market for lung cancer diagnostics is estimated to be in the billions of dollars. OncoCyte is targeting a specific segment of this market with DetermaRx.
Upturn SWOT Analysis
Strengths
- Proprietary diagnostic technology
- Focus on lung cancer
- Potential for early cancer detection
- Non-invasive testing
Weaknesses
- Limited market share
- Dependence on a single product (DetermaRx)
- Requires significant marketing and sales efforts
- Cash burn
Opportunities
- Expansion into other cancer types
- Partnerships with pharmaceutical companies
- Increased adoption of liquid biopsy tests
- Regulatory approvals
Threats
- Competition from larger diagnostic companies
- Technological advancements in competing methods
- Reimbursement challenges
- Clinical trial failures
Competitors and Market Share
Key Competitors
- TMO
- DHR
- ILLM
- STVN
Competitive Landscape
OncoCyte faces competition from established diagnostic companies with greater resources. Its competitive advantage lies in its focus on lung cancer and non-invasive testing methods.
Growth Trajectory and Initiatives
Historical Growth: Historical growth depends on previous years' results. See SEC filings for specifics.
Future Projections: Future projections are unavailable at this point and would depend on analyst estimations.
Recent Initiatives: Recent initiatives include expanding sales and marketing efforts for DetermaRx.
Summary
OncoCyte Corp. is a small company in the liquid biopsy diagnostics sector. It focuses on lung cancer with its DetermaRx test. It has strong potential but faces considerable competition and financial challenges. The company needs to successfully commercialize its products to achieve sustained growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Market research reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OncoCyte Corp
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2016-01-04 | President, CEO & Director Mr. Joshua Riggs | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 46 | Website https://www.oncocyte.com |
Full time employees 46 | Website https://www.oncocyte.com | ||
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.